Obtaining a biopsy from patients with advanced or metastasized cancer.
Patients with advanced or metastasized cancer who will be receiving a standard treatment with anti-cancer medication.
The growth of a cancerous tumor is very complex significant changes occur in the tumor’s genetic material (DNA) over time in patients with cancer. While these mutations in the DNA make the tumor increasingly aggressive, they also help us distinguish who will and will not benefit from a given treatment. At a later stage we may even be able to develop a treatment specifically focused on the mutations in the DNA of the tumor. The goal of the CPCT-02 study is to look at the DNA profile of the tumor and study the link between the DNA profile and responses to therapy.
Patients eligible for this study are those with advanced or metastasized cancer who will be receiving a standard treatment with anti-cancer medication. We will take a segment (biopsy) of the tumor before and during treatment. Thanks to a new technology (Next Generation DNA Sequencing) we can now simultaneously identify all major mutations in the DNA of the tumor (the profile). Precisely because the tumor is constantly changing it is important to have insight into the mutations in the DNA before the treatment starts. Moreover, we want to find indications in the DNA as to whether someone does or does not respond well during treatment and after the treatment has finished.
Because this is a new method it is not possible to guarantee that the patients will have a proven effective treatment at a later stage. Once the patient’s DNA profile is known, however, we can and will do our utmost to involve the patients in pharmaceutical research that suits their DNA profile.
For more information about possible participation, contact your own oncologist or an oncologist in one of the participating centers. You can also contact Neeltje Steeghs, internist oncologist at the Antoni van Leeuwenhoek hospital and principal researcher on the study.